Colorectal Cancer Organoid Expansion for Drug Discovery: Method Selection for Analysing Organoids

Jessica Pinheiro De Lucena-Thomas, Kimberley Luetchford (Editor), Marianne Ellis (Editor)

Research output: Contribution to conferencePoster

Abstract

Around 95% of new drug candidates that are studied in humans fail
to be both effective and safe.1,2 Therefore, it is crucial to use better
predictive toxicology models to move towards more successful clinical
translation and consequently improve people`s lives by providing
better healthcare treatments.
 Simple models have been used previously, such as 2D monolayer
cultures, 3D spheroids cultures and tissue explants, but all of these
present a large gap between the cellular level and the organ level.3
The development of a 3D model called organoids has provided a
better in vitro biological model with the potential to improve the
drug discovery process. They can better predict drug efficacy and
toxicity, while reducing the need for animal models in the drug discovery
pipeline. In this context, Cellesce has developed a new bioprocessing technology
for large scale expansion of organoids, ensuring that there are enough organoids of high quality to enable their application by the pharmaceutical industry. This project analyzed the product, by size and number, using three techniques, improved the organoid expansion process.

Fingerprint

Organoids
Drug Discovery
Colorectal Neoplasms
Biological Models
Drug Industry
Pharmaceutical Preparations
Toxicology
Animal Models
Technology
Delivery of Health Care

Cite this

Pinheiro De Lucena-Thomas, J., Luetchford, K. (Ed.), & Ellis, M. (Ed.) (2017). Colorectal Cancer Organoid Expansion for Drug Discovery: Method Selection for Analysing Organoids. Poster session presented at CSCT Summer Showcase 2017, Bath, UK United Kingdom.

Colorectal Cancer Organoid Expansion for Drug Discovery: Method Selection for Analysing Organoids. / Pinheiro De Lucena-Thomas, Jessica; Luetchford, Kimberley (Editor); Ellis, Marianne (Editor).

2017. Poster session presented at CSCT Summer Showcase 2017, Bath, UK United Kingdom.

Research output: Contribution to conferencePoster

Pinheiro De Lucena-Thomas, J, Luetchford, K (ed.) & Ellis, M (ed.) 2017, 'Colorectal Cancer Organoid Expansion for Drug Discovery: Method Selection for Analysing Organoids' CSCT Summer Showcase 2017, Bath, UK United Kingdom, 10/07/17 - 11/07/17, .
Pinheiro De Lucena-Thomas J, Luetchford K, (ed.), Ellis M, (ed.). Colorectal Cancer Organoid Expansion for Drug Discovery: Method Selection for Analysing Organoids. 2017. Poster session presented at CSCT Summer Showcase 2017, Bath, UK United Kingdom.
Pinheiro De Lucena-Thomas, Jessica ; Luetchford, Kimberley (Editor) ; Ellis, Marianne (Editor). / Colorectal Cancer Organoid Expansion for Drug Discovery: Method Selection for Analysing Organoids. Poster session presented at CSCT Summer Showcase 2017, Bath, UK United Kingdom.
@conference{9f0575b57936473cbe39a9b1f9749d84,
title = "Colorectal Cancer Organoid Expansion for Drug Discovery: Method Selection for Analysing Organoids",
abstract = "Around 95{\%} of new drug candidates that are studied in humans failto be both effective and safe.1,2 Therefore, it is crucial to use betterpredictive toxicology models to move towards more successful clinicaltranslation and consequently improve people`s lives by providingbetter healthcare treatments. Simple models have been used previously, such as 2D monolayercultures, 3D spheroids cultures and tissue explants, but all of thesepresent a large gap between the cellular level and the organ level.3The development of a 3D model called organoids has provided abetter in vitro biological model with the potential to improve thedrug discovery process. They can better predict drug efficacy andtoxicity, while reducing the need for animal models in the drug discoverypipeline. In this context, Cellesce has developed a new bioprocessing technologyfor large scale expansion of organoids, ensuring that there are enough organoids of high quality to enable their application by the pharmaceutical industry. This project analyzed the product, by size and number, using three techniques, improved the organoid expansion process.",
author = "{Pinheiro De Lucena-Thomas}, Jessica and Kimberley Luetchford and Marianne Ellis",
year = "2017",
month = "7",
day = "10",
language = "English",
note = "CSCT Summer Showcase 2017 : Sustainable Chemical Technologies for a Circular Economy ; Conference date: 10-07-2017 Through 11-07-2017",
url = "http://www.bath.ac.uk/publications/csct-summer-showcase-2017-programme/",

}

TY - CONF

T1 - Colorectal Cancer Organoid Expansion for Drug Discovery: Method Selection for Analysing Organoids

AU - Pinheiro De Lucena-Thomas, Jessica

A2 - Luetchford, Kimberley

A2 - Ellis, Marianne

PY - 2017/7/10

Y1 - 2017/7/10

N2 - Around 95% of new drug candidates that are studied in humans failto be both effective and safe.1,2 Therefore, it is crucial to use betterpredictive toxicology models to move towards more successful clinicaltranslation and consequently improve people`s lives by providingbetter healthcare treatments. Simple models have been used previously, such as 2D monolayercultures, 3D spheroids cultures and tissue explants, but all of thesepresent a large gap between the cellular level and the organ level.3The development of a 3D model called organoids has provided abetter in vitro biological model with the potential to improve thedrug discovery process. They can better predict drug efficacy andtoxicity, while reducing the need for animal models in the drug discoverypipeline. In this context, Cellesce has developed a new bioprocessing technologyfor large scale expansion of organoids, ensuring that there are enough organoids of high quality to enable their application by the pharmaceutical industry. This project analyzed the product, by size and number, using three techniques, improved the organoid expansion process.

AB - Around 95% of new drug candidates that are studied in humans failto be both effective and safe.1,2 Therefore, it is crucial to use betterpredictive toxicology models to move towards more successful clinicaltranslation and consequently improve people`s lives by providingbetter healthcare treatments. Simple models have been used previously, such as 2D monolayercultures, 3D spheroids cultures and tissue explants, but all of thesepresent a large gap between the cellular level and the organ level.3The development of a 3D model called organoids has provided abetter in vitro biological model with the potential to improve thedrug discovery process. They can better predict drug efficacy andtoxicity, while reducing the need for animal models in the drug discoverypipeline. In this context, Cellesce has developed a new bioprocessing technologyfor large scale expansion of organoids, ensuring that there are enough organoids of high quality to enable their application by the pharmaceutical industry. This project analyzed the product, by size and number, using three techniques, improved the organoid expansion process.

M3 - Poster

ER -